Skip to main content Accessibility help

Antimalarial interaction of quinine and quinidine with clarithromycin



Quinine (QN) and quinidine (QND) have been commonly used as effective and affordable antimalarials for over many years. Quinine primarily is used for severe malaria treatment. However, plasmodia resistance to these drugs and poor patient compliance limits their administration to the patients. The declining sensitivity of the parasite to the drugs can thus be dealt with by combining with a suitable partner drug. In the present study QN/QND was assessed in combination with clarithromycin (CLTR), an antibiotic of the macrolide family. In vitro interactions of these drugs with CLTR against Plasmodium falciparum (P. falciparum) have shown a synergistic response with mean sum fractional inhibitory concentrations (ΣFICs) of ⩽1 (0·85 ± 0·11 for QN + CLTR and 0·64 ± 0·09 for QND + CLTR) for all the tested combination ratios. Analysis of this combination of QN/QND with CLTR in mouse model against Plasmodium yoelii nigeriensis multi-drug resistant (P. yoelii nigeriensis MDR) showed that a dose of 200 mg/kg/day for 4 days of QN or QND produces 100% curative effect with 200 mg/kg/day for 7 days and 150 mg/kg/day for 7 days CLTR respectively, while the same dose of individual drugs could produce only up to a maximum 20% cure. It is postulated that CLTR, a CYP3A4 inhibitor, might have caused reduced CYP3A4 activity leading to increased plasma level of the QN/QND to produce enhanced antimalarial activity. Further, parasite apicoplast disruption by CLTR synergies the antimalarial action of QN and QND.


Corresponding author

*Corresponding author: Division of Parasitology, P.O.Box No. 173, Central Drug Research Institute (CSIR), Chattar Manzil Palace, Lucknow 226001, India. Tel: +91 522 2612411-18 Extn. 4461. Fax: +91 522 2623405/2623938. E-mail:


Hide All
Achan, J., Talisuna, A. O., Erhart, A., Yeka, A., Tibenderana, J. K., Baliraine, F. N., Rosenthal, P. J. and D'Alessandro, U. (2011). Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria. Malaria Journal 10, 144.
Awasthi, A., Dutta, G. P., Bhakuni, V. and Tripathi, R. (2004). Resistance reversal action of ketoconazole against mefloquine resistance of Plasmodium yoelii nigeriensis (MDR). Experimental Parasitology 107, 115119.
Barat, L. M. and Bloland, P. B. (1997). Drug resistance among malaria and other parasites. Infectious Disease Clinics of North America 11, 969987.
Bhattacharya, A., Mishra, L. C., Sharma, M., Awasthi, S. K. and Bhasin, V. K. (2009). Antimalarial pharmacodynamics of chalcone derivatives in combination with artemisinin against Plasmodium falciparum In vitro. European Journal of Medicinal Chemistry 44, 33883393.
Calza, P., Medana, C., Padovano, E., Giancotti, V. and Baiocchi, C. (2012). Identification of the unknown transformation products derived from clarithromycin and carbamazepine using liquid chromatography/high-resolution mass spectrometry. Rapid Communications in Mass Spectrometry 26, 16871704.
Champney, W. S., Tober, C. L. and Burdine, R. (1998). A comparison of the inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by nine different macrolide antibiotics. Current Microbiology 37, 412417.
Damkier, P. and Brosen, K. (2000). Quinidine as a probe for CYP3A4 activity: Intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clinical Pharmacology & Therapeutics 68, 199209.
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., Ringwald, P., Silamut, K., Imwong, M., Chotivanich, K., Lim, P., Herdman, T., An, S. S., Yeung, S., Singhasivanon, P., Day, N. P. J., Lindegardh, N., Socheat, D. and White, N. J. (2009). Reduced in-vivo susceptibility of Plasmodium falciparum to artesunate in Western Cambodia. New England Journal of Medicine 361, 455467.
Dorne, J. L. C. M., Walton, K. and Renwick, A. G. (2003). Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food and Chemical Toxicology 41, 201224.
Einarson, A., Phillips, E., Mawji, F., D'Alimonte, D., Schick, B., Addis, A., Mastroiacova, P., Mazzone, T., Matsui, D. and Koren, G. (1998). A prospective controlled multicentre study of clarithromycin in pregnancy. American Journal of Perinatology 15, 523525.
Ekland, E. H., Schneider, J. and Fidock, D. A. (2011). Identifying apicoplast-targeting antimalarials using highthroughput compatible approaches. The FASEB Journal 25, 35833593.
Ho, P., Luo, X., Macauley, J. S., Grigor, M. R. and Wanwimolruk, S. (1998). In vitro hepatic metabolism of cyp3a-mediated drugs quinine and midazolam in the common brush-tailed possum (trichosurus vulpecula). Environmental Toxicology and Chemistry 17, 317324.
Johnson, J. D., Richard, A. D., Lucia, G., Miriam, L., Norma, E. R. and Norman, C. W. (2007). Assessment and continued validation of the malaria SYBR Green I-based fluorescence assay for use in malaria drug screening. Antimicrobial Agents and Chemotherapy 51, 19261933.
Kalanon, M. and McFadden, G. I. (2010). Malaria, Plasmodium falciparum and its apicoplast. Biochemical Society Transactions 38, 775782.
Kazim, M., Puri, S. K. and Dutta, G. P. (1991). Comparative evaluation of blood schizontocidal activity of quinine and quinidine against drug resistant rodent malaria. Journal of Communicable Diseases 23, 254256.
King, S. M. (1995). Clarithromycin for children. Canadian Journal of Infectious Diseases 6, 6970.
Lell, B. and Kremsner, P. G. (2002). Clindamycin as an antimalarial drug: review of clinical trials. Antimicrobial Agents and Chemotherapy 46, 23152320.
Mathis, A., Wild, E. C., Boettger, E. C., Kapel, C. M. O. and Deplazes, C. P. (2005). The mitochondrial ribosome as target for macrolide antibiotic clarithromycin in the helminth Echinococcus multiocularis. Antimicrobial Agents and Chemotherapy 49, 32513255.
Mathis, A., Wild, P., Deplazes, P. and Boettger, E. C. (2004). The mitochondrial ribosome of the protozoan Acanthamoeba castellanii is the target for macrolide antibiotics. Molecular and Biochemical and Parasitology 135, 225229.
Mirghani, R. A., Yasar, U., Zheng, T., Cook, J. M., Gustafsson, L. L., Tybring, G. and Ericsson, O. (2002). Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro: 3-hydroxylation by cyp3a4 is indeed the major metabolic pathway. Drug Metabolism and Disposition 30, 13681371.
Na-Bangchang, K. and Karbwang, J. (2009). Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development. Fundamental & Clinical Pharmacology 23, 387409.
Nand, N., Aggarwal, H., Sharma, M. and Singh, M. (2001). Systemic Manifestations of Malaria. Journal, Indian Academy of Clinical Medicine 2, 189194.
Newton, P., Keeratithakul, D., Teja-Isavadharm, P., Pukrittayakamee, S., Kyle, D. and White, N. (1999). Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. Transactions of Royal Society of Tropical Medicine & Hygiene 93, 6972.
Nielsen, T. L., Rasmussen, B. B., Flinois, J., Beaune, P. and Brosen, K. (1999). In vitro metabolism of quinidine: the (3 s)-3-hydroxylation of quinidine is a specific marker reaction for cytochromep-4503a4 activity in human liver microsomes. The Journal of Pharmacology and Experimental Therapeutics 289, 3137.
Pai, M. P., Graci, D. M. and Amesden, G. W. (2000). Macrolide-drug interaction: an update. Annals of Pharmacotherapy 34, 495513.
Pinto, A. G., Wanq, Y. H., Chalasani, N., Skaar, T., Kolwankar, D., Gorski, J. C., Lianqpunsaqul, S., Hamman, M. A., Arefayene, M. and Hall, S. D. (2005). Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P4503A4/5 activity and expression. Clinical Pharmacological Therapy 77, 178188.
Rodrigues, A. D., Roberts, E. M., Mulford, D. J., Yao, Y. and Ouellet, D. (1997). Oxidative metabolism of clarithromycin in the presence of human liver microsomes: major role for the cytochrome p4503a (cyp3a) subfamily. Drug Metabolism and Disposition 25, 623630.
Sidhu, A. B. S., Valderramos, S. G. and David, A. (2005). Fidock PfMDR 1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Molecular Microbiology 57, 913926.
Singh, S., Srivastava, R. K., Srivastava, M., Puri, S. K. and Srivastava, K. (2011). In-vitro culture of Plasmodium falciparum: utility of modified (RPNI) medium for drug-sensitivity studies using SYBR Green I assay. Experimental Parasitology 127, 318321.
Soyinka, J. O., Onyeji, C. O., Omoruyi, S. I., Owolabi, A. R., Sarma, P. V. and Cook, J. M. (2009). Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. British Journal of Clinical Pharmacology 69, 262270.
Sullivan, D. J. Jr., Gluzman, I., Russell, D. G. and Goldberg, D. E. (1996). On the molecular mechanism of chloroquine's antimalarial action. Proceedings of the National Academy of Sciences USA 93, 1186511870.
Suzuki, A., Iida, I., Hirota, M., Akimoto, M., Huguchi, S., Suwa, T., Tani, M., Ishizaki, T. and Chiba, K. (2003). CYP isoforms involved in the metabolism of clarithromycin in vitro: Comparison between the identification from the disappearance rate and that from formation rate of metabolites. Drug Metabolism and Pharmacokinetics 18, 104113.
Tripathi, R., Pandey, S. K. and Rizvi, A. (2011). Clarithromycin, a cytochrome P450 inhibitor, can reverse mefloquine resistance in Plasmodium yoelii nigeriensis infected Swiss mice. Parasitology 138, 10691076.
Tripathi, R., Awasthi, A. and Dutta, G. P. (2005). Mefloquine resistance reversal action of ketoconazole-A cytochrome P450 inhibitor, against mefloquine resistant malaria. Parasitology 130, 475479.
Uzuegbu, U. E. and Emeka, C. B. (2011). Changes in Liver Function Biomarkers among Malaria Infected Patients in Ikeja Lagos State, Nigeria. Current Research Journal of Biological Sciences 3, 172174.
Ward, M. B., Sorich, M. J., Evans, A. M. and McKinnon, R. A. (2009). Cytochrome P450 Part 3: Impact of Drug–Drug Interactions. Journal of Pharmacy Practice and Research 39, 5558.
White, N. J., Looareesuwan, S., Warrell, D. A., Chongsuphajaisiddhi, T., Bunnag, D. and Harinasuta, T. (1981). Quinidine in falciparum malaria. Lancet 4, 10691071.
Whitty, C. J. M., Chandler., Ansah, E., Leslie, T. and Staedke, S. G. (2008). Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malaria Journal 7, (Suppl 1):S7.
Wisedpanichkij, R., Chaijaroenkula, W., Sangsuwanb, P., Tantisawat, J., Boonpraserta, K. and Na-Bangchanga, K. (2009). In vitro antimalarial interactions between mefloquine and cytochrome P450 inhibitors. Acta Tropica 112, 1215.
Wongsrichanalai, C., Pickard, A. L., Wernsdorfer, W. H. and Meshnick, S. R. (2002). Epidemiology of drug-resistant malaria. Lancet Infectious Diseases 2, 209218.
World Health Organization. (2012). Update on Artemisinin ResistanceApril.
World Health Organization. (2006). Malaria Treatment Guidelines and Artemisinin Monotherapies. Geneva, Switzerland.
Zuckerman, J. M., Qamar, F. and Bono, B. R. (2009). Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infectious Disease Clinics of North America 23, 9971026.


Antimalarial interaction of quinine and quinidine with clarithromycin



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed